Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, I.P. Pavlova 6, 77520, Olomouc, Czech Republic,
J Neural Transm (Vienna). 2013 Nov;120(11):1559-63. doi: 10.1007/s00702-013-1020-2. Epub 2013 Apr 16.
Chromogranin A (CgA) levels in cerebrospinal fluid (CSF) have been reported to be significantly reduced in the later stages of Parkinson's disease (PD). There are only limited data regarding its levels in the early stages, so its significance as a potential biomarker in the diagnosis of PD cannot be established. The aim of our study was to establish the level of CgA in a cohort of treatment-naïve patients with early stage PD. Ten patients (4 males, 6 females) and 10 gender- and age-matched controls were examined for CgA levels in the CSF. Control subjects were patients with low-back pain or tension-type headache. The mean CSF CgA level in PD patients was 74.8 (41.9-123.8) μg/l; in the control group it was 143.9 (116-181.3) μg/l. Statistical analysis showed a difference at the significance level P ≤ 0.05. Our pilot study shows that CSF CgA levels are reduced in the early stages of PD. CgA could therefore be a potential biomarker helpful in the diagnosis of PD.
在帕金森病（PD）的后期阶段，脑脊液（CSF）中的嗜铬粒蛋白 A（CgA）水平据报道显著降低。关于其在早期阶段的水平仅有有限的数据，因此其作为 PD 潜在诊断生物标志物的意义尚不能确定。我们的研究旨在确定未经治疗的早期 PD 患者队列中的 CgA 水平。检查了 10 名患者（4 名男性，6 名女性）和 10 名性别和年龄匹配的对照组的 CSF 中的 CgA 水平。对照组为腰痛或紧张性头痛患者。PD 患者的平均 CSF CgA 水平为 74.8（41.9-123.8）μg/l；对照组为 143.9（116-181.3）μg/l。统计分析显示在 P ≤ 0.05 的显著水平上存在差异。我们的初步研究表明，CSF CgA 水平在 PD 的早期阶段降低。因此，CgA 可能是有助于 PD 诊断的潜在生物标志物。
